In this GEN webinar, our speakers will present important considerations for quality control testing for biosafety and product ...

Cell therapies, including CAR-T cells, and gene therapies, represent some of the forefront advancements in modern medicine. As we witness rapid technological and clinical advancements, the global ...

University of Wisconsin–Madison researchers targeting a group of hereditary neurodegenerative diseases have found success ...

Cell and gene therapy companies are the beneficiaries of positive changes along the regulatory path that the U.S. FDA is ...

To improve long-term persistence and reduce the risk of immune rejection, researchers are exploring ways to diminish the ...

Multiple players are exploring whether modalities designed to combat B cell malignancies can be repurposed against lupus, ...

New data publishing 11/11 in Cell Stem Cell provides strong support for the first-in-human universal gene therapy trial for DBA through regulated GATA1 expression. Notably, it’s one of the first ...

BEAM-101 seems to be competitive with approved sickle cell treatments, William Blair analysts said in a note to investors, ...

Its lead gene therapy candidate has the potential to be faster, less expensive, and more widely available than current CAR T ...

We recently published a list of 10 Most Promising Gene Editing Stocks to Buy According to Hedge Funds. In this article, we ...

Beam Therapeutics enrolls 35 patients in BEACON trial for BEAM-101 in sickle cell disease, with promising early safety and ...

The death, which investigators linked to a preparatory chemo treatment rather than Beam's medicine, highlights the risks of using decades-old transplant drugs alongside cutting-edge CRISPR medicines.